CISAPRIDE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H29ClFN3O4
Molecular Weight	465.945
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C3=C(OC)C=C(N)C(Cl)=C3

InChI

InChIKey=DCSUBABJRXZOMT-IRLDBZIGSA-N

InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H29ClFN3O4
Molecular Weight	465.945
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.rxlist.com/propulsid-drug.htm
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/pro/propulsid.html | http://www.marvistavet.com/cisapride.pml

Cisapride is chemically related to metoclopramide, but unlike metoclopramide, it does not cross the blood-brain barrier or have antidopaminergic effects. Cisapride is a serotonin-4 (5-HT4) receptor agonist. Cisapride was indicated for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease. The Food and Drug Administration (FDA) in America stopped the marketing of cisapride as of 14th July 2000. They had received at least 341 reports of heart rhythm abnormalities and these led to 80 deaths. Other reported adverse effects are: headache, diarrhea, abdominal pain, nausea, constipation. Cisapride for animals has been found helpful in some cases of megaesophagus and is a common treatment for feline megacolon. Clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride. Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serotonin 4 (5-HT4) receptor 39 Target ID: CHEMBL1875 Sources: http://www.rxlist.com/propulsid-drug.htm	Agonist 2662	41.5 nM [Ki]
Cytochrome P450 3A4 126 Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10780971	Substrate 656
Cytochrome P450 2A6 15 Target ID: CHEMBL5282 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10780971	Substrate 656

Conditions

Condition	Modality	Highest Phase	Product
Gastroesophageal reflux disease 60 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20767-S011_Propulsid.pdf	Palliative	Withdrawn	PROPULSID Approved Use Cisapride is indicated for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease. Launch Date 7.4390399E11
Megacolon 3 Sources: https://cdn.ymaws.com/www.aavpt.org/resource/resmgr/imported/cisapride.pdf	Primary	Not Provided 503	Unknown Approved Use Unknown
Constipation 112 Sources: https://cdn.ymaws.com/www.aavpt.org/resource/resmgr/imported/cisapride.pdf	Primary	Not Provided 503	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
7.5 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	NORCISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
75.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg 4 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
115.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	20 mg 4 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
190.4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	40 mg 4 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
69.5 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
88.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	NORCISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1193 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg 4 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1925 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	20 mg 4 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2978 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	40 mg 4 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
719 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
8.2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	NORCISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.77 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg 4 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.98 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	20 mg 4 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.76 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	40 mg 4 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
0.2 mg/kg 4 times / day steady, oral Recommended Dose: 0.2 mg/kg, 4 times / day Route: oral Route: steady Dose: 0.2 mg/kg, 4 times / day Co-administed with:: erythromycin Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 1 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	Other AEs: Arrhythmia... Other AEs: Arrhythmia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/
0.2 mg/kg 4 times / day steady, oral Recommended Dose: 0.2 mg/kg, 4 times / day Route: oral Route: steady Dose: 0.2 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 58000 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 58000 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	Other AEs: Diarrhea... Other AEs: Diarrhea (12 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/
2 mg/kg 4 times / day steady, oral Studied dose Dose: 2 mg/kg, 4 times / day Route: oral Route: steady Dose: 2 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 2 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	Other AEs: Arrhythmia... Other AEs: Arrhythmia (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/

AEs

AE	Significance	Dose	Population
Arrhythmia	1 patient	0.2 mg/kg 4 times / day steady, oral Recommended Dose: 0.2 mg/kg, 4 times / day Route: oral Route: steady Dose: 0.2 mg/kg, 4 times / day Co-administed with:: erythromycin Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 1 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/
Diarrhea	12 patients	0.2 mg/kg 4 times / day steady, oral Recommended Dose: 0.2 mg/kg, 4 times / day Route: oral Route: steady Dose: 0.2 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 58000 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 58000 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/
Arrhythmia	2 patients	2 mg/kg 4 times / day steady, oral Studied dose Dose: 2 mg/kg, 4 times / day Route: oral Route: steady Dose: 2 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 2 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709		inhibitor 1837 substrate 1193	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1437	P-gp 1527 CYP1A2 1032 CYP2C19 985 CYP2A6 523 CYP2E1 648

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2D6 1875	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/10859153/	yes [Ki 14 uM]
P-gp 1626	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12621386/	yes [Ki 16.1 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1527	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12621386/	no
CYP1A2 1032	substrate 3326 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP2A6 523	substrate 3326 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP2C19 985	substrate 3326 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP2D6 1193	substrate 3326 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP2E1 648	substrate 3326 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20767-S011_Propulsid.pdf#page=10;https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246 Page: 10.0	yes	yes (co-administration study) Comment: Ketoconazole resulted in an 8 fold increase and fluconazole more than doubled the AUC of cisapride. Many other DDIs: see https://pubmed.ncbi.nlm.nih.gov/10926350/ Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20767-S011_Propulsid.pdf#page=10;https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246 Page: 10.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://pubmed.ncbi.nlm.nih.gov/9374794/

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific, Inc. (AKSCI)	3553AH	http://www.aksci.com/item_detail.php?cat=3553AH
Alfa Chemistry	AP260779882-A	https://reagents.alfa-chemistry.com/product/cisapride-cas-260779-88-2-8872.html
Alfa Chemistry	AP260779882-B	https://reagents.alfa-chemistry.com/product/cisapride-monohydrate-cas-260779-88-2-8873.html
Alichem	129009439	http://www.alichem.com/en/products/260779-88-2.html
Aurora Fine Chemicals LLC	A17.904.038	http://online.aurorafinechemicals.com/info?ID=A17.904.038
AvaChem Scientific	2794H	http://www.avachem.com/productSearch.asp?2794H
BOC Sciences	260779-88-2	https://www.bocsci.com/cisapride-hydrate-cas-260779-88-2-item-103946.html
Chemspace	CSSB00020619548	https://chem-space.com/CSSB00020619548
Clearsynth	CS-O-15504	https://www.clearsynth.com/en/CSO15504.html
Glentham Life Sciences	GL0434	http://www.glentham.com/products/product/GL0434/
Lab Network	LN01806108	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01806108
MolPort	MolPort-016-638-372	https://www.molport.com/shop/molecule-link/MolPort-016-638-372
MolPort	MolPort-044-674-489	https://www.molport.com/shop/molecule-link/MolPort-044-674-489
Selleck Chemicals	S4751	http://www.selleckchem.com/products/cisapride.html
Sigma-Aldrich	C4740_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/c4740?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1134120_USP	https://www.sigmaaldrich.com/catalog/product/usp/1134120?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S567175	https://www.smolecule.com/products/s567175
abcr GmbH	AB511558	http://www.abcr.de/shop/en/AB511558

PubMed

Title	Date	PubMed
Fluorometric screening for metabolism-based drug--drug interactions.	2000 Jul-Aug	11274899
Efficacy and tolerability of cisapride in children.	2001	11577921
Comparative safety of the different macrolides.	2001	11574199
Saquinavir soft gelatin capsule: a comparative safety review.	2001	11347724
Controversies in the management of chronic constipation.	2001	11321420
Drug treatment options for irritable bowel syndrome: managing for success.	2001	11302287
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.	2001	11293643
Synergistic and antagonistic pharmacodynamic interaction between ranitidine and cisapride: a study on the isolated rabbit intestine.	2001 Apr	11352537
[Current indications for cisapride].	2001 Apr	11339124
Cisapride decreases gastroesophageal reflux in preterm infants.	2001 Apr	11335779
Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function.	2001 Apr	11316178
Postoperative ileus: a preventable event (Br J Surg 2000; 87: 1480-93).	2001 Apr	11298634
Postoperative ileus: a preventable event (Br J Surg 2000; 87: 1480-93).	2001 Apr	11298633
Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy.	2001 Apr 11	11308395
Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats.	2001 Aug	11555327
Enteral feeding in the critically ill: comparison between the supine and prone positions: a prospective crossover study in mechanically ventilated patients.	2001 Aug	11511335
A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.	2001 Aug	11510389
No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease.	2001 Aug	11507354
Survey of primary care physicians' approach to gastroesophageal reflux disease in elderly patients.	2001 Aug	11487605
[Irritable colon].	2001 Aug 20	11530562
Cisapride and the Vanessa Young inquest.	2001 Aug 21	11531044
Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.	2001 Aug-Sep	11569530
[Acid-related disease in the population of two Norwegian municipalities--diagnosis and drug therapy].	2001 Feb 20	11301609
Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole.	2001 Jan	11334262
[Anorexia nervosa or somatic disease].	2001 Jul	11547640
A randomized, double-blind placebo-controlled trial of the effects of the 5-hydroxytriptamine(4) agonist cisapride on the female urinary bladder.	2001 Jul	11483905
Effects of cisapride on ventricular depolarization-repolarization and arrhythmia markers in infants.	2001 Jul	11474146
Cisapride improves gallbladder emptying and bile lipid composition in patients with gallstones.	2001 Jul	11446892
Pharmacological characterization of a novel 5-HT4 receptor agonist, TS-951, in vitro.	2001 Jul	11408827
Pneumatosis intestinalis in a patient with polymyositis.	2001 Jul-Aug	11491518
Study of the drug-drug interaction between simvastatin and cisapride in man.	2001 Jun	11497338
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.	2001 Jun	11419817
"Use-dependent" effects of cisapride on postrest action potentials in rabbit ventricular myocardium.	2001 Jun 22	11430924
Effect of cisapride on gastric sensitivity to distension, gastric compliance and duodeno-gastric reflexes in healthy humans.	2001 Jun-Jul	11529652
Discriminative stimulus properties of indorenate in a conditioned taste aversion paradigm.	2001 Mar	11325395
Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis.	2001 Mar	11280535
[Gynecomastia associated with the simultaneous use of cisapride and lansoprazole].	2001 Mar 24	11333695
Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters.	2001 May	11501334
Drug safety: can simple interventions be effective in a complex world?	2001 May	11501333
Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug.	2001 May	11448055
Mechanisms of cisapride affecting gallbladder motility.	2001 May	11341662
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.	2001 May	11336111
Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: Pharmacological profile.	2001 May	11334836
Review article: erythromycin as a prokinetic agent in infants and children.	2001 May	11328252
Cisapride and patient information leaflets.	2001 May 1	11341134
Lessons from cisapride.	2001 May 1	11341130
Canada needs better drug reporting, says inquest.	2001 May 5	11356458
The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease.	2001 Sep	11552909
[Drug therapy of functional dyspepsia. A review based on Cochrane Reviews].	2001 Sep 10	11573368
QT interval effects of cisapride in the clinical setting.	2001 Sep-Oct	11578711

Patents

Sample Use Guides

In Vivo Use Guide

Initiate therapy with one 10 mg tablet or 10 mL of the suspension 4 times daily at least 15 minutes before meals and at bedtime. In some patients the dosage will need to be increased to 20 mg, given as above, to obtain a satisfactory result.

Route of Administration: Oral

In Vitro Use Guide

The addition of Cisapride to the mucosal solution to give a concentration of 6 x 10-5 M caused a transient rise in potential difference (PD, P < 0.05) and short-circuit current (SCC, P < 0.05) with no significant (P > 0.05) change in tissue resistance.

Substance Class	Chemical Created by `admin` on `Thu Jul 06 22:48:37 UTC 2023` Edited by `admin` on `Thu Jul 06 22:48:37 UTC 2023`
Record UNII	UVL329170W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CISAPRIDE

Official Name

English

CISAPRIDE [HSDB]

Common Name

English

CISAPRIDE [MI]

Common Name

English

CISAPRIDE [JAN]

Common Name

English

R-51619

Code

English

CISAPRIDE [USAN]

Common Name

English

CIS-4-AMINO-5-CHLORO-N-(1-(3-(P-FLUOROPHENOXY)PROPYL)-3-METHOXY-4-PIPERIDYL)-O-ANISAMIDE

Common Name

English

cisapride [INN]

Common Name

English

CISAPRIDE [USP-RS]

Common Name

English

Cisapride [WHO-DD]

Common Name

English

CISAPRIDE [VANDF]

Common Name

English

R-51,619

Code

English

BENZAMIDE, 4-AMINO-5-CHLORO-N-(1-(3-(4-FLUOROPHENOXY)PROPYL)-3-METHOXY-4-PIPERIDINYL)-2-METHOXY-, CIS

Common Name

English

CISAPRIDE [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA03FA02